Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Fevipiprant in Hepatic Impairment
NCT03048448Phase 1Completed
- Sponsor
- Novartis
- Start
- May 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fevipiprant in asthma (2 arms), sponsored by Novartis. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration, Area under the plasma concentration-time curve from time zero to infinity and 1 more. Started May 2017; status: completed.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03048448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03048448.